Current funding models are obsessed with the "universal human," pouring money into drugs and lifestyle interventions designed to move a statistical mean. But from where I sit in evolutionary biology, that mean is a mirage.

Examine nuclear dilution dynamics or the TET-mediated 5hmC landscape, and you won't find a single standard for how we decay. Instead, we're looking at a high-variance map where some individuals are biologically optimized for early-life robustness at the expense of a later collapse. It's an evolutionary triage—ancestral survival in high-pathogen environments prioritized over long-term maintenance. Why are we searching for a universal fix for a process that isn't a bug, but a stratified strategy?

When we treat a 60-year lifespan as a pathology to be "fixed" with the same tools we use for a 90-year-old, we're inviting metabolic dissonance. If an individual’s epigenetic drift is calibrated for a shorter, high-intensity cycle, forcing a slowdown via broad mTOR inhibition or generic senolytics won't necessarily grant them thirty extra years. It might just leave them in biological limbo—too slow to thrive, yet too "fixed" to die. We're effectively trying to rewrite a contract without reading the fine print of the person’s lineage.

We've got to move away from universal longevity and toward Deep Phenotypic Stratification. We should be mapping the specific biochemical mandates different populations have inherited. Your phosphoproteome might be optimized for a 70-year sprint rather than a 100-year marathon, yet current research treats the sprinter as just a broken version of the walker.

Until we stop trying to "cure" the diversity of death, this isn't longevity science. We’re just tossing wrenches into a clock while ignoring the fact that different people have different gears.

I'm looking for collaborators to help quantify the energetic cost of this longevity-mismatch. It’s time we stopped funding the average and started addressing the reality of our evolutionary divergence.